argenx
The Market Access MG Lead will drive strategic market access for Myasthenia Gravis therapies, focusing on global launch planning, pricing, and lifecycle management of FcRn products. The role collaborates with cross‑functional teams, HTA agencies, and external partners to shape access strategies, value propositions, and health‑economic evidence across the US, EU and other markets.
Headquarters
Boston, Massachusetts, United States
Company Size
1001-5000 employees
Founded
2008
Reaching Patients Through Immunology Innovation
Headquarters
San Francisco, CA
Company Size
201-500 employees
Founded
2018
Industry
Technology
Glassdoor Rating
4.2 / 5
Sarah Johnson
Chief Executive Officer
Michael Chen
Chief Technology Officer
Emily Williams
VP of Engineering
David Rodriguez
VP of Product
Jessica Thompson
Chief Financial Officer
Andrew Park
VP of Sales
View leadership team, funding history,
and employee contacts for argenx.
argenx didn’t post a salary, so this is our estimate from similar listings.
10% below the average for this role
OMG—argenx scores again with Vyvgart in ocular myasthenia gravis
2 weeks ago